FindMyKOL
Clinical trialNCT07123649RecruitingPhase 2Interventional

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

NCT07123649 is a phase 2 interventional trial sponsored by Dana-Farber Cancer Institute. As of 18 Nov 2026, it is recruiting participants. It studies Breast Cancer. The registry lists an enrollment of 364 participants at 1 site in 1 country. The registry lists a start date of 11 Sept 2025 and a primary completion date of 11 Sept 2027.

SponsorDana-Farber Cancer Institute →Enrollment364Breast Cancer
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT07123649
FieldValue
Registry IDNCT07123649
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorDana-Farber Cancer Institute
Enrollment364
Registered sites1
Countries1
ConditionsBreast Cancer
Start11 Sept 2025
Primary completion11 Sept 2027
Study completion11 Sept 2029
Last update posted22 Apr 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Massachusetts, United States1 site, 1 recruiting
  • Dana-Farber Cancer Institute

    Boston

    Rachel Freedman, MD, MPH
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 1 site, 1 recruitingMA1Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT07123649

Each answer restates registry values shown on this page.

What is NCT07123649?

NCT07123649 is a phase 2 interventional trial sponsored by Dana-Farber Cancer Institute. It studies Breast Cancer.

Is NCT07123649 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT07123649?

The registry names Rachel Freedman, MD, MPH (principal investigator, Dana-Farber Cancer Institute) as the overall official.

Where does NCT07123649 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT07123649 expected to complete?

The registry lists a primary completion date of 11 Sept 2027 and a study completion date of 11 Sept 2029. The sponsor last updated the record on 22 Apr 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.